NEW YORK – Drugmakers Edison Oncology and Apollomics on Thursday said they have begun studying EO1001 in a Phase I/IIa trial involving patients with ErbB-positive solid tumors.
The first patient has received the pan-ErbB inhibitor EO1001 in this trial, which is being conducted at multiple clinical sites in Australia under a contract service provided by Senz Oncology, the companies noted. Researchers will explore the safety and tolerability of EO1001 in up to 50 patients with advanced ErbB-positive tumors, including those with EGFR, HER2, and ERbB4-altered cancers. Patients with tumors that have spread to the central nervous system can also partake in the trial.
Preclinical studies have shown that EO1001 is active against EGFR activating mutations that show up in non-small cell lung cancer, such as T790M, L858R, and d746-750; HER2-positive breast tumors; and glioblastomas characterized by the siEGFR-variant III. ErbB pathway mutations are also oncogenic drivers of endometrial, ovarian, bladder, and other cancers.
Earlier this year, Edison and Foster City, California-headquartered Apollomics signed a licensing deal, which gives Apollomics rights to develop and commercialize EO1001 globally, except in mainland China, Hong Kong, and Taiwan. Apollomics is also developing a MET inhibitor APL-101 in a variety of MET dysregulated tumors.